Empagliflozin
- PDF / 169,655 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 63 Downloads / 178 Views
1 S
Euglycaemic diabetic ketoacidosis: case report A 58-year-old man developed euglycaemic diabetic ketoacidosis (euDKA) during treatment with empagliflozin for type 2 diabetes mellitus (T2DM). The man, who was diagnosed with T2DM due to pancreatic adenocarcinoma, was admitted to the emergency department with a one-day history of slurred speech, fever and excessive thirst on 23 October 2019. Vital signs revealed pulse rate of 124 beats/min, BP of 90/60 mm Hg and body temperature of 38°C. Initial laboratory findings revealed glycosuria, increased levels of serum ketone, anion gap, serum glucose, C-reactive protein, procalcitonin and leucocytes and decreased levels of serum sodium and serum bicarbonate. It was reported that he had been receiving treatment with empagliflozin 10mg once daily [route not stated] from 14 days since 7 October 2019. Additionally, he was receiving treatment with metformin concomitantly. Based on these findings and clinical presentation, he was diagnosed with euDKA associated with empagliflozin [time to reaction onset not clearly stated]. The man was treated with insulin infusion, hydration therapy and unspecified broad-spectrum antibiotics. Thereafter, in 12 hours euDKA resolved. Sezer H, et al. Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer. Endokrynologia Polska 803501674 71: 283-284, No. 3, Jan 2020
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
